<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373435</url>
  </required_header>
  <id_info>
    <org_study_id>EIG-EXD-001</org_study_id>
    <nct_id>NCT03373435</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia</brief_title>
  <acronym>PREVENT</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eiger BioPharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eiger BioPharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will evaluate whether taking an investigational drug called exendin 9-39
      is safe, well-tolerated, and helps to prevent low blood sugar in people who have had
      bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicenter, randomized, single-blind, placebo-controlled cross-over study
      in patients with refractory PBH.

      Participants will be randomized and assigned in a 1:1 ratio to one of two treatment arms. All
      participants will receive 2 dosing regimens of exendin 9-39 and matching placebo
      self-administered via subcutaneous (SC) injection.

      Participants will undergo in-clinic mixed meal tolerance test (MMTT) provocation with
      concomitant blood draws and symptom assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Actual">October 15, 2018</completion_date>
  <primary_completion_date type="Actual">September 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial Hypoglycemia</measure>
    <time_frame>3 hours following a liquid meal</time_frame>
    <description>Plasma glucose nadir occurring within 3 hours of MMTT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>An adverse event can be any unfavorable and unintended sign, symptom, or disease that occurs during the study treatment periods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity score of postprandial neuroglycopenic signs and symptoms calculated from patients' responses to the Edinburgh Hypoglycemia Symptom Scale. (EHSS).</measure>
    <time_frame>3 hours following a liquid meal</time_frame>
    <description>Neuroglycopenic symptoms evaluated by the EHSS include blurred vision, confusion, drowsiness, speech difficulty, incoordination, dizziness, and inability to concentrate. Patients will complete the EHSS approximately every 30 minutes during each MMTT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial hyperinsulinemia.</measure>
    <time_frame>3 hours following a liquid meal</time_frame>
    <description>Peak postprandial insulin concentration in response to MMTT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Postbariatric Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive two dose regimens of exendin 9-39 and one placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive two dose regimens of exendin 9-39 and one placebo (in a different sequence than Treatment Group 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exendin 9-39</intervention_name>
    <description>Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.</description>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_label>Treatment Group 2</arm_group_label>
    <other_name>Glucagon-like peptide-1 (GLP-1) antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.</description>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_label>Treatment Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) of up to 40 kg/m2

          -  Roux-en-Y gastric bypass (RYGB) surgery performed â‰¥12 months prior

          -  Diagnosis of PBH

          -  At least 2 episodes during screening 2-week run-in phase of severe hypoglycemia

        Exclusion Criteria:

          -  Other cause of endogenous hyperinsulinism other than PBH

          -  Metabolic or bariatric surgical procedure other than RYGB

          -  History of non-RYGB upper GI surgery

          -  Use of agents that may interfere with glucose metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen Craig, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eiger BioPharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Early Phase Clinical Research</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <disposition_first_submitted>January 27, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>January 27, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 6, 2020</disposition_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

